Paul McNally

Associate Professor
RCSI University of Medicine and Health Sciences

Poster(s):

• (163) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and ≥1 F508del allele: 96-week interim results from an open-label extension study
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (166) Measuring adherence to chronic therapies over the first year of treatment with Elexacaftor/Tezacaftor/Ivacaftor in people with Cystic Fibrosis (CF)
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (251) Evaluation of Medication Electronic Monitoring Systems (MEMS®) in Adherence Measurement in the real world setting
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (283) Expectations and experiences of adolescents with cystic fibrosis: influence of Elexacaftor/Tezacaftor/Ivacaftor on treatment adherence and identity
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET